Liquid chromatographic assay for the protease inhibitor atazanavir in plasma

Rolf W. Sparidans, Frits Dost, Kristel M.L. Crommentuyn, Alwin D.R. Huitema, Jan H.M. Schellens, Jos H. Beijnen

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

17 Citaten (Scopus)


Atazanavir is the most recently introduced protease inhibitor for the suppression of the anti-human immunodefficiency virus. A selective reversed-phase liquid chromatographic assay for this drug in human plasma has been developed and validated. Atazanavir was isolated from a 500 μL plasma sample using liquid-liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using liquid chromatography and ultraviolet detection at 280 nm. In the evaluated concentration range (44-4395 ng/mL atazanavir), intra-day precisions were ≤7% and inter-day precisions were ≤14%. Accuracies between 96 and 106% were found. The lower limit of quantification was 44 ng/mL with an intra-day precision of 7%, an inter-day precision of 14% and an accuracy of 87%. There was no interference from 32 tested potentially co-administrated drugs and metabolites. The usefulness of the assay was demonstrated for samples obtained from an HIV-infected patient treated with atazanavir.

Originele taal-2Engels
Pagina's (van-tot)72-76
Aantal pagina's5
TijdschriftBiomedical Chromatography
Nummer van het tijdschrift1
StatusGepubliceerd - jan. 2006
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Liquid chromatographic assay for the protease inhibitor atazanavir in plasma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit